Raia Drogasil S.A (RADL3)
Sao Paulo Exchange · Brazil · prices in BRL · close of 16 Oct 2026
Key indicators
| Last close | BRL 20.56 |
|---|---|
| 52-week range | 16.10 – 27.13 |
| Return, 1 month / 3 months | +1.6% / +10.8% |
| Return, 1 year / 3 years | +14.3% / −20.3% |
| Trend | Below its 200-day average |
| RSI (14) | 55 |
| Volatility (1 year) | 36.3% |
| Worst drawdown (1 year) | -39.6% |
| Average daily value traded | 208.15M BRL |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Raia Drogasil is a Brazilian pharmacy retailer that runs a chain of drugstores across the country. Its stores sell prescription and over-the-counter medicines, personal care items, beauty products and everyday health and household goods. The company serves individual consumers through its retail outlets and also offers online ordering and delivery. It is based in Brazil and operates under the Droga Raia and Drogasil banners, which together form one of the country's familiar pharmacy networks.
On this site Raia Drogasil S.A appears as a stock on the Sao Paulo Exchange (Brazil), code RADL3, with prices in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Raia Drogasil S.A (RADL3) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 20.56 on 16 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 655 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.3% and over the last three months it rose 10.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 36 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -1.8% | ||
| From 52-week high | -23.0% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 10.8% | ||
| 6-month return | -11.0% | ||
| 12-month return, skipping the last month | 12.5% | ||
| Stability (higher is calmer) | 45 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 36.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.6% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 208.15M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 55 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.2% |
|---|---|
| 1 month | +1.6% |
| 3 months | +10.8% |
| 6 months | −11.0% |
| 1 year | +14.3% |
| 3 years | −20.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 19.46 / 20.93 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.86 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jul 2026 | BRL 0.1156 |
| 6 Apr 2026 | BRL 0.0860 |
| 5 Dec 2025 | BRL 0.1640 |
| 3 Oct 2025 | BRL 0.0838 |
| 3 Jul 2025 | BRL 0.0785 |
| 29 Apr 2025 | BRL 0.0619 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.